Study of VS-7375 for cancers with a KRAS G12D mutation
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Women’s health & pregnancy clinical trials.
This study tests an experimental drug called VS-7375 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of cancer that has spread or cannot be removed with surgery, and it must have a KRAS G12D mutation (a specific genetic change).
- You must have at least one tumor that can be measured on a scan.
- You should be able to take care of yourself (light activity or better).
- Your organs (like kidneys, liver, heart) must be working well enough, and you must have recovered from side effects of previous treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted pill, VS-7375, for people with a specific type of advanced colorectal cancer called KRAS G12D. It's for those who either haven't had treatment yet or whose cancer has worsened after prior therapy.
This trial tests a new drug combination for people with a specific KRAS mutation in pancreatic cancer. It aims to see if the treatment can shrink tumors or slow the disease.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
This study tests a new drug (ASP5834) for people with advanced solid tumors that have changes in the KRAS gene. The study looks for a safe and effective dose, and may help you if your standard treatments have stopped working.
This trial tests a new drug, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. It's for those who have already tried chemo and immunotherapy, and whose cancer has continued to grow.
This trial tests an experimental drug (GDC-7035) given with other cancer treatments to see if it is safe and works in people with advanced colorectal or pancreatic cancer that has a specific genetic change called KRAS G12D.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.